Pfizer announces positive study results for its Abrysvo in immunocompromised adults at risk of developing lower respiratory tract disease associated with severe respiratory syncytial virus (RSV).

According to sub-study B of the ongoing pivotal phase III MONeT clinical trial, this vaccine was well tolerated and generated strong neutralizing responses after a single dose in immunocompromised individuals aged 18 years or older.

"These results add to the growing body of evidence indicating that a single dose of Abrysvo offers strong immune protection against RSV outcomes", the pharmaceutical giant points out.

Pfizer plans to share these results at an upcoming scientific conference and publish them in a peer-reviewed scientific journal, as well as submit these data to regulatory agencies for review.

Copyright (c) 2024 CercleFinance.com. All rights reserved.